

# Clinical Outcomes of Non-carbapenem Treatment for Urinary Tract Infections Caused by Extended-spectrum $\beta$ -lactamase-producing *Escherichia coli*

Eunae Kim, M.D.<sup>1</sup>  
Yo Han Ahn, M.D., Ph.D.<sup>2,3,4</sup>  
Jung Won Lee, M.D., Ph.D.<sup>5</sup>  
Eujin Park, M.D., Ph.D.<sup>1</sup>

<sup>1</sup>Department of Pediatrics, Hallym University Kangnam Sacred Heart Hospital, Seoul, South Korea; <sup>2</sup>Department of Pediatrics, Seoul National University Children's hospital, Seoul, South Korea; <sup>3</sup>Department of Pediatrics, Seoul National University College of Medicine, Seoul, South Korea; <sup>4</sup>Kidney Research Institute, Seoul National University Medical Research Center, Seoul, South Korea; <sup>5</sup>Department of Pediatrics, Ewha Womans University School of Medicine, Seoul, South Korea

**Corresponding author:** Eujin Park, M.D., Ph.D.

Department of Pediatrics, Hallym University Kangnam Sacred Heart Hospital, 665 Siheung-daero, Yeongdengpo-gu, Seoul, South Korea

**Tel:** +82-2-6960-1300

**Fax:** +82-849-4469

**E-mail:** [eujinpark@hallym.or.kr](mailto:eujinpark@hallym.or.kr)

Received: 20 April 2021

Revised: 10 May 2021

Accepted: 7 June 2021

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/4.0/>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Copyright © 2021 The Korean Society of Pediatric Nephrology

**Purpose:** The purpose of this study was to investigate the clinical outcomes of non-carbapenem treatment for urinary tract infections (UTIs) caused by extended-spectrum  $\beta$ -lactamase (ESBL)-producing *Escherichia coli* (*E. coli*) in young children.

**Methods:** We retrospectively reviewed the medical records of children under 2 years of age who were diagnosed and treated for UTIs caused by ESBL-producing *E. coli* from September 2014 to March 2020.

**Results:** Forty-three children under 2 years of age were treated with non-carbapenem antimicrobials for UTIs caused by ESBL-producing *E. coli* without bloodstream infections. The overall clinical and microbiological success rates for empirical antimicrobial treatment were 90.7% and 97.7%. Three of the patients (7.0%) experienced a relapse of UTI within a month. An *in vitro* susceptibility test showed that two patients were sensitive and one was resistant to the antimicrobial treatments. Furthermore, there were no significant differences in the time to defervescence, clinical success, microbiological success, and relapse rate between the susceptible (n=13) and non-susceptible groups (n=30).

**Conclusion:** In this study, the overall relapse rate of patients treated with non-carbapenem antimicrobials was 7.0%. The patients showed high success rates in the clinical and microbiological responses to the non-carbapenems regardless of the results of the *in vitro* antimicrobial susceptibility test. These results provide evidence that non-carbapenems may be viable alternative treatments for UTIs caused by ESBL-producing *E. coli*.

**Key words:** Beta-Lactamases, Urinary tract infection, Beta-Lactamase inhibitors, Cephalosporin

## Introduction

Urinary tract infections (UTIs) caused by extended-spectrum  $\beta$ -lactamase (ESBL)-producing organisms are increasingly becoming prevalent<sup>1-5</sup>. ESBL is an enzyme produced by Gram-negative bacterial species that hydrolyze most of the  $\beta$ -lactam antibiotics, including cephalosporin and penicillin<sup>6-8</sup>. Carbapenem is the most potent and broadest  $\beta$ -lactam antibiotics because it has an unsaturated bond between C2 and C3, and the carbon atom replaces the sulfur atom in the thiazolidine ring in the penicillin core structure. It is considered as the gold standard treatment for ESBL infections<sup>9,10</sup>. However, due to the possible emergence of carbapenem-resistant organisms, and a lack

of therapeutic options in the event of carbapenem treatment failure, clinicians continue to raise concerns about the overuse of carbapenem and are contemplating over strategies for its selective use<sup>11-15</sup>.

Most clinicians experience improvement in clinical symptoms and the achievement of microbiological responses without the use of carbapenem in children with UTIs caused by ESBL-producing organisms. This phenomenon is difficult to explain clearly; however, the clinical and microbiological responses to antimicrobials used for UTIs and bloodstream infections are presumably different, since the urine drug concentration is generally higher than that achieved systemically<sup>16-19</sup>. As such, *in vitro* antimicrobial susceptibility test results in patients with UTIs caused by ESBL-producing organisms are not always helpful in predicting the recurrence of UTIs or kidney scarring. Since few studies have been reported on this issue in the pediatric population, insufficient evidence is available to support the use of non-carbapenem antimicrobials as therapeutic options for cases of uncomplicated UTIs caused by ESBL-producing organisms that are responsive to initially administered antimicrobials<sup>17,20-23</sup>. Therefore, clinicians keep questioning whether antimicrobials should be changed based on the results of *in vitro* antimicrobial susceptibility tests, despite clinical and microbiological success with the initial empirical antimicrobials. This study attempts to address the matter by investigating the clinical outcomes of non-carbapenem treatment for UTIs caused by ESBL-producing *Escherichia coli* (*E. coli*) in young children.

## Materials and Methods

### 1. Study design and definitions

We reviewed the electronic medical records of individuals diagnosed with UTIs caused by ESBL-producing *E. coli* between September 2014 to March 2020 at Hallym University Kangnam Sacred Heart Hospital. All patients under 2 years of age with a single microbial infection confirmed by the isolation of ESBL-producing *E. coli* from urine samples and without bloodstream infections were included. All urine sample collections were obtained via urinary catheterization. Patients who met all three criteria below were considered to have UTI. The axillary body temperature

measured in the hospital was  $>38^{\circ}\text{C}$  ( $100.4^{\circ}\text{F}$ ), the number of bacterial colonies in urine culture was above  $5 \times 10^4/\text{mL}$ , and pyuria was greater than 5 white blood cells (WBCs) per high power field (HPF). The antimicrobial given to each patient was chosen after careful discussion with the patient's parents about the available antimicrobials and their pros and cons. This study was approved by the institutional review board of Hallym University Kangnam Sacred Heart Hospital (IRB 2020-05-003).

The antimicrobial susceptibility test was performed with a disc diffusion test recommended by the Clinical and Laboratory Standards Institute guidelines<sup>24</sup>. Antimicrobial therapy administered before *in vitro* antimicrobial susceptibility test results were available was considered empirical, whereas antimicrobial therapy administered afterward was considered definitive. Patients who started effective empirical therapy or had subsequently switched to susceptible antimicrobials during the course of their infection were classified as "susceptible", whereas patients who received non-susceptible antimicrobials for the treatment of their current UTI episode were classified as "non-susceptible". The main outcome variables were time to defervescence, clinical success, microbiological success, and relapse. Time to defervescence was defined as the time that patient maintain a body temperature below  $38^{\circ}\text{C}$  ( $100.4^{\circ}\text{F}$ ) without the help of antipyretics after the initiation of antimicrobials. Clinical success was defined as resolution of signs and symptoms within 3 days after the start of treatment. Microbiological success was defined as a negative urine culture within 3 days after the start of antimicrobial treatment. Patients who developed UTI caused by the same pathogen within a month after treatment initiation were considered relapse cases.

### 2. Statistical analyses

We used the median and interquartile range (IQR) to express continuous variables and percentages to express categorical variables. The Mann-Whitney test was used to evaluate differences in continuous variables, and chi-squared test or Fisher's exact test was used to evaluate differences in categorical variables between groups. *P*-value  $<0.05$  was considered to be statistically significant. We used IBM SPSS Statistics for Windows, Version 26.0 (IBM Corp, Armonk, NY) for all analyses.

## Results

### 1. Study population and baseline characteristics

During the study period, 43 children treated with non-carbapenem for UTIs caused by ESBL-producing *E. coli* were identified. Third-generation cephalosporin, cefotaxime, was the most commonly administered empirical antimicrobial agents (37/43, 86.0%), whereas in remaining cases,  $\beta$ -lactam/ $\beta$ -lactamase inhibitor (6/43, 14.0%), piperacillin/tazobactam, was used. The antimicrobial agent was changed in 7 patients, from third-generation cephalosporin to  $\beta$ -lactam/ $\beta$ -lactamase inhibitor based on *in vitro* antimicrobial susceptibility test results (Fig. 1).

The overall median age of patients was 6 months (IQR 4.0–9.0) and 24 patients were male (55.8%). With regards previous medical history, 6 patients (14.0%) had an underlying urologic disorder such as congenital hydronephrosis and mild pelviectasia, 4 patients (9.3%) had previously experienced UTIs, and 11 patients (25.6%) had been previously hospitalized. All patients underwent kidney ultrasonography (USG) and 16 patients (37.2%) showed abnormalities. Of the 20 patients who underwent the Tc-99m dimercaptosuccinic acid renal scan (DMSA) during the acute phase, 3 patients (15.0%) were found with cortical defects. Vesicoureteral reflux was found in 1 out of 11 patients (9.1%) who underwent voiding cystourethrography (VCUG). Since the number of patients who underwent DMSA and VCUG was small, statistical analysis could not be performed. In all patients, the strains isolated were sensitive to carbapenem and resistant to cefotaxime, a third-




Fig. 1. Flow chart of patients included in the study. 3<sup>rd</sup> Cephalosporin, third-generation cephalosporin; BLBLI,  $\beta$ -lactam/ $\beta$ -lactamase inhibitor.

generation cephalosporin. Of the strains isolated, amoxicillin-clavulanic acid were sensitive to 28 (65.1%) and piperacillin-tazobactam were sensitive to 41 (95.3%). The median total duration of fever before admission was 24 hours and the median total duration of treatment was 13 days (IQR 10.0–14.0) (Table 1).

### 2. Comparison between susceptible and non-susceptible groups

As shown in Table 1, 30.2% of patients (13 of 43) were susceptible and 69.8% of patients (30 of 43) were non-susceptible to treated non-carbapenem antimicrobials. No statistically significant differences were found in the demographics, medical histories, total duration of fever before admission and total duration of treatment days between susceptible and non-susceptible groups. In laboratory test results, C-reactive protein level was higher in the susceptible group than in the non-susceptible group ( $P=0.044$ ), and the levels of other inflammatory markers such as white blood cell count, erythrocyte sedimentation rate and pyuria were not significantly differ between the two groups.

The clinical outcomes of patients stratified by *in vitro* antimicrobial susceptibility are presented in Table 2. Both the susceptible and non-susceptible groups had high clinical and microbiological success rates in response to the empirical antimicrobial treatments (overall clinical success rate=90.7%; overall microbiological success rate=97.7%). Fever subsided about 6 hours after the initiation of antimicrobials in both groups. The relapse rate was higher in the susceptible group than in the non-susceptible group, but a statistically significant difference was not observed. In total, 3 patients (7.0%) experienced relapse.

### 3. Patients who experienced relapse of urinary tract infection

Patients who experienced relapse after the completion of treatment with non-carbapenem treatment are presented in Table 3. One patient was resistant to definitive antimicrobial treatments (cefotaxime), whereas the other two patients were sensitive to definitive antimicrobial treatments (piperacillin/tazobactam) by *in vitro* antimicrobial susceptibility test results. None of these patients had an underlying urologic disorder, a history of UTIs, or previous hospitalization history. All of them had abnormal image

findings on USG: two had thickened renal pelvis walls and one had hydronephrosis in the left kidney. Two patients underwent DMSA and VCUG, and the results were normal.

All the relapse patients achieved clinical and microbiological success with cefotaxime as the empirical antimicrobial treatment. The two later switched to piperacillin/tazobac-

**Table 1. Demographics and clinical characteristics of patients treated with non-carbapenem antimicrobials**

Variables	Overall (N=43)	Susceptible (N=13)	Non-susceptible (N=30)	P-value
<b>Patients</b>				
Onset months	6.0 (4.0–9.0)	7.0 (4.5–9.5)	6.0 (4.0–9.5)	0.784
Sex (Male)	24 (55.8%)	8 (61.5%)	16 (53.3%)	0.619
<b>History</b>				
Underlying urologic disorder	6 (14.0%)	3 (23.1%)	3 (10.0%)	0.345
Urinary tract infection	4 (9.3%)	2 (15.4%)	2 (6.7%)	0.572
Hospitalization	11 (25.6%)	5 (38.5%)	6 (20.0%)	0.262
<b>Laboratory findings</b>				
WBC (/μL)	13280 (10,440–17,010)	14,390 (12,690–18,010)	12,050 (9,458–17,025)	0.130
ESR (mm/hr)	17.0 (10.0–34.0)	25.0 (15.0–68.5)	16.0 (6.75–28.75)	0.062
CRP (mg/L)	21.8 (9.1–40.2)	35.2 (12.9–72.3)	15.1 (8.5–31.7)	0.044
<b>Pyuria (/HPF)</b>				
<20	7 (16.3%)	2 (15.4%)	5 (16.7%)	0.987
20–49	7 (16.3%)	2 (15.4%)	5 (16.7%)	
>50	29 (67.4%)	9 (69.2%)	20 (66.7%)	
<b>Abnormal image findings</b>				
Kidney USG	16 (37.2%)	7 (53.8%)	9 (30.0%)	0.178
DMSA	3/20 (15.0%)	2/5 (40.0%)	1/15 (6.7%)	-
VCUG	1/11 (9.1%)	1/5 (20.0%)	0/6 (0%)	-
Total duration of fever before admission (hours)	24.0 (12.0–48.0)	24.0 (11.0–48.0)	24.0 (12.0–48.0)	0.957
Total duration of treatment (days)	13.0 (10.0–14.0)	13.0 (10.0–14.0)	13.5 (10.8–14.3)	0.505

WBC, white blood cell; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; USG, ultrasonography; DMSA, Tc-99m dimercaptosuccinic acid renal scan; VCUG, voiding cystourethrography.

Statistical analysis was performed by using the chi-squared test or Fisher's exact test and the Mann-Whitney test, as appropriate.

**Table 2. Clinical outcomes of patients treated with non-carbapenem antimicrobials**

Variables	Overall (N=43)	Susceptible (N=13)	Non-susceptible (N=30)	P-value
Time to defervescence (hours)	6.0 (1.0–22.0)	6.0 (2.0–24.0)	5.5 (1.0–20.5)	0.667
Clinical success	39 (90.7%)	12 (92.3%)	27 (90.0%)	1.000
Microbiological success	42 (97.7%)	13 (100.0%)	29 (96.7%)	1.000
Relapse	3 (7.0%)	2 (15.4%)	1 (3.3%)	0.213

Statistical analysis was performed by using the Fisher's exact test and the Mann-Whitney test, as appropriate.

**Table 3. Description of patients with relapse of urinary tract infection**

Patient ID	Onset months/Sex	Image findings	<i>In vitro</i> antimicrobial susceptibility to definitive antibiotics (MICs, μg/mL)	Relapse (weeks)
ID32	1/M	Renal pelvis wall thickening on USG No cortical defect on DMSA No VUR on VCUG	Cefotaxime R 8	3
ID40	5/F	Hydronephrosis, left kidney on USG No cortical defect on DMSA	Piperacillin/tazobactam S ≤4	2
ID43	9/M	Renal pelvis wall thickening on USG No VUR on VCUG	Piperacillin/tazobactam S ≤4	4

USG, ultrasonography; DMSA, Tc-99m dimercaptosuccinic acid renal scan; VUR, vesicoureteral reflux; VCUG, voiding cystourethrography; R, resistant; S, sensitive.

tam based on the results of their *in vitro* antimicrobial susceptibility tests. When they relapsed, one patient who was resistant to the definitive treatment received piperacillin/tazobactam and two patients who were sensitive to the definitive treatment were treated with ertapenem. All three patients were found to be sensitive to the treated antimicrobials by *in vitro* antimicrobial susceptibility test and no longer relapsed.

## Discussion

Carbapenems are considered a gold standard treatment for infections due to ESBL-producing strains, even if the patient's infection is already clinically responsive to other  $\beta$ -lactams<sup>25,26</sup>. However, indiscriminate carbapenem use dramatically increases the prevalence of carbapenem-resistant *Enterobacteriaceae*, which poses a serious threat to public health. Clinicians should carefully consider alternative strategies to minimize carbapenem use<sup>11-13,27,28</sup>. Another problem with carbapenem use also rises from a practical perspective. Carbapenems are designed to be used only intravenously; no other option for treatment is available if the patient cannot be hospitalized immediately or if a peripheral or central intravenous catheter can not be placed. On the other hand, non-carbapenems can be administered orally as well as intravenously<sup>29</sup>. Therapeutic options using non-carbapenems for UTIs caused by ESBL-producers is of great importance for the pediatric population, which commonly suffers from peripheral or central intravenous catheterization failure in clinical practice due to smaller and less visible veins<sup>30,31</sup>.

Few studies have been conducted on the efficacy of non-

carbapenem treatment for UTIs caused by ESBL-producing organisms in children (Table 4). Our results are generally consistent with previous reports, confirming that even without carbapenem treatment, children with UTIs caused by ESBL-producers had high clinical and microbiological success rates and low relapse rates. Tratselas et al. reported that although most of the patients (24 of 28) in their study (children with UTI caused by ESBL-producers) received empirical antimicrobial treatments that were incongruent to their *in vitro* antimicrobial susceptibility test findings, the overall clinical and microbiological success rates were 94.4% and 95.0%, respectively. At follow-up, the formation of kidney scars in these patients did not significantly differ compared with children with UTIs caused by non-ESBL-producers<sup>20</sup>. Peco-Antić et al. suggested that the *in vitro* resistance of ESBL-producing *E. coli* to ceftriaxone, a third-generation cephalosporin, did not necessarily indicate *in vivo* sensitivity. They found that clinical and microbiological responses to ceftriaxone were similar between UTIs caused by ESBL-producers and those by non-ESBL-producers<sup>17</sup>. These results are also consistent with previous studies in South Korean populations. Lee et al. and Han et al. confirmed that children treated with non-carbapenems for UTIs caused by ESBL-producing strains showed favorable clinical outcomes<sup>21,22</sup>. Hyun et al. reported that the relapse rate in children with UTIs caused by ESBL-producers did not differ significantly with those treated with susceptible antimicrobials or with those treated with non-susceptible but clinically effective antimicrobials<sup>23</sup>. These findings are in line with those of studies on the use of cephalosporin or  $\beta$ -lactam/  $\beta$ -lactamase inhibitors for the treatment of ESBL infections in adults, with the conclusion that several non-carbapenems are not inferior to carbape-

**Table 4. Previous studies evaluating the efficacy of non-carbapenem treatment for urinary tract infections caused by extended-spectrum  $\beta$ -lactamase producing *Enterobacteriaceae***

Study	N	Organisms	Sources of infection	Non-carbapenems	Clinical outcomes
Tratselas et al. <sup>20</sup>	28	<i>E. coli</i> (67.9%)	Urinary (100%)	Cephalosporin (2 <sup>nd</sup> & 3 <sup>rd</sup> ), Amoxicillin/clavulanate, Amikacin	Clinical success 94.4% Microbiological success 95.0%
Peco-Antić et al. <sup>17</sup>	94	<i>E. coli</i> (100%)	Urinary (100%)	Ceftriaxone	Clinical success 81.6% Microbiological success 87.5%
Lee et al. <sup>21</sup>	28	<i>E. coli</i> (67%)	Urinary (100%) Blood stream (5%)	Cefotaxime, Amikacin, Piperacillin-tazobactam	Relapse 4.0%, Treatment success 100%
Han et al. <sup>22</sup>	22	<i>E. coli</i> (95.5%)	Urinary (100%)	Cephalosporin (2 <sup>nd</sup> & 3 <sup>rd</sup> ), Amoxicillin/clavulanate, Amikacin	Clinical success 90.9% Microbiological success 100%
Hyun et al. <sup>23</sup>	146	<i>E. coli</i> (80.1%)	Urinary (100%)	Cefotaxime, Aminoglycoside, Piperacillin-tazobactam	Relapse: susceptible 2.3% Non-susceptible 3.3%

nems and deserve consideration as an alternative options for ESBL infections, depending on the source of infection and severity of illness<sup>32-35</sup>.

In this study, the overall relapse rate was 7.0% (3 of 43). We found no significant differences in the clinical characteristics and treatment outcomes according to the results of *in vitro* antimicrobial susceptibility test except for C-reactive protein level between the susceptible and non-susceptible groups. Both groups had high clinical and microbiological success rates regardless of the results of *in vitro* antimicrobial susceptibility test (overall 90.7% and 97.7%, respectively). Our findings suggest that non-carbapenems may be useful as alternative therapy for UTIs caused by ESBL-producing *E. coli*, if clinical improvements are presented.

Although the data from our study will add value to efforts to spare carbapenem as few studies have studied the efficacy of non-carbapenem treatments with UTIs caused by ESBL-producers in pediatric population, this study has several limitations. First, this is a retrospective observational study from a single center with a small sample size. Second, due to very small number of relapsed patients, risk factors for relapse after non-carbapenem treatment could not be evaluated. Although most patients were followed up for a month after discharge, there is a possibility that some patient visited another hospital when there were symptoms of relapse. Third, because identification for the type of  $\beta$ -lactamase enzymes in *E. coli* was not performed, their association with clinical outcomes cannot be assessed.

In conclusion, we found that non-carbapenem treatment for UTIs caused by ESBL producing *E. coli* in children under 2 years of age had high clinical and microbiological success rates, regardless of *in vitro* antimicrobial susceptibility test results, with an overall relapse rate of 7.0%. These results provide evidence that non-carbapenems are viable alternative treatments for UTIs caused by ESBL-producing *E. coli*. However, further prospective studies with large sample sizes and in-depth investigation of laboratory evidence are required to establish conclusive findings.

## Funding

This research did not receive any specific grant from

funding agencies in the public, commercial, or not-for-profit sectors.

## Conflicts of interest

No potential conflict of interest relevant to this article was reported.

## ORCID

Eunae Kim <https://orcid.org/0000-0001-7940-4240>

Yo Han Ahn <https://orcid.org/0000-0002-8185-4408>

Jung Won Lee <https://orcid.org/0000-0003-1846-3153>

Eujin Park <https://orcid.org/0000-0002-4413-468X>

## References

1. Zorc JJ, Kiddoo DA, Shaw KN. Diagnosis and management of pediatric urinary tract infections. *Clin Microbiol Rev* 2005;18:417-22.
2. Briongos-Figuero LS, Gómez-Traveso T, Bachiller-Luque P, Domínguez-Gil González M, Gómez-Nieto A, Palacios-Martín T, et al. Epidemiology, risk factors and comorbidity for urinary tract infections caused by extended-spectrum beta-lactamase (ESBL)-producing enterobacteria. *Int J Clin Pract* 2012;66:891-6.
3. Jean SS, Coombs G, Ling T, Balaji V, Rodrigues C, Mikamo H, et al. Epidemiology and antimicrobial susceptibility profiles of pathogens causing urinary tract infections in the Asia-Pacific region: Results from the Study for Monitoring Antimicrobial Resistance Trends (SMART), 2010-2013. *Int J Antimicrob Agents* 2016;47:328-34.
4. Megged O. Extended-spectrum  $\beta$ -lactamase-producing bacteria causing community-acquired urinary tract infections in children. *Pediatr Nephrol* 2014;29:1583-7.
5. Fan NC, Chen HH, Chen CL, Ou LS, Lin TY, Tsai MH, et al. Rise of community-onset urinary tract infection caused by extended-spectrum  $\beta$ -lactamase-producing *Escherichia coli* in children. *J Microbiol Immunol Infect* 2014;47:399-405.
6. Oteo J, Pérez-Vázquez M, Campos J. Extended-spectrum (beta)-lactamase producing *Escherichia coli*: changing epidemiology and clinical impact. *Curr Opin Infect Dis* 2010;23:320-6.
7. Wong-Beringer A, Hindler J, Loeloff M, Queenan AM, Lee N, Pegues DA, et al. Molecular correlation for the treatment outcomes in bloodstream infections caused by *Escherichia coli* and *Klebsiella pneumoniae* with reduced susceptibility to ceftazidime. *Clin Infect Dis* 2002;34:135-46.

8. Tinelli M, Cataldo MA, Mantengoli E, Cadeddu C, Cunietti E, Luzzaro F, et al. Epidemiology and genetic characteristics of extended-spectrum  $\beta$ -lactamase-producing Gram-negative bacteria causing urinary tract infections in long-term care facilities. *J Antimicrob Chemother* 2012;67:2982-7.
9. Papp-Wallace KM, Endimiani A, Taracila MA, Bonomo RA. Carbapenems: past, present, and future. *Antimicrob Agents Chemother* 2011;55:4943-60.
10. Ramphal R, Ambrose PG. Extended-spectrum beta-lactamases and clinical outcomes: current data. *Clin Infect Dis* 2006;42 Suppl 4:S164-72.
11. Apisarnthanarak A, Hsu LY, Khawcharoenporn T, Mundy LM. Carbapenem-resistant Gram-negative bacteria: how to prioritize infection prevention and control interventions in resource-limited settings? *Expert Rev Anti Infect Ther* 2013;11:147-57.
12. Poirel L, Nordmann P. Carbapenem resistance in *Acinetobacter baumannii*: mechanisms and epidemiology. *Clin Microbiol Infect* 2006;12:826-36.
13. Park JY. Should we prescribe carbapenem for treating febrile urinary tract infection caused by extended-spectrum  $\beta$ -lactamase-producing Enterobacteriaceae in children with vesicoureteral reflux? *Clin Exp Pediatr* 2021.
14. Doi A, Shimada T, Harada S, Iwata K, Kamiya T. The efficacy of cefmetazole against pyelonephritis caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae. *Int J Infect Dis* 2013;17:e159-63.
15. Sethaphanich N, Santanirand P, Rattanasiri S, Techasaensiri C, Chaisavaneeyakorn S, Apiwattanukul N. Pediatric extended spectrum  $\beta$ -lactamase infection: Community-acquired infection and treatment options. *Pediatr Int* 2016;58:338-46.
16. Guet-Revillet H, Emirian A, Groh M, Nebbad-Lechani B, Weiss E, Join-Lambert O, et al. Pharmacological study of cefoxitin as an alternative antibiotic therapy to carbapenems in treatment of urinary tract infections due to extended-spectrum- $\beta$ -lactamase-producing *Escherichia coli*. *Antimicrob Agents Chemother* 2014;58:4899-901.
17. Peco-Antić A, Paripović D, Buljugić S, Spasojević-Dimitrijeva B, Cvetković M, Laban-Nestorović S, et al. In vivo susceptibility of ESBL producing *Escherichia coli* to ceftriaxone in children with acute pyelonephritis. *Srp Arh Celok Lek* 2012;140:321-5.
18. Gentry LO. Cephalosporins in urinary tract infection. *Drugs* 1987;34 Suppl 2:154-63.
19. Vinks AA, Derendorf H, Mouton JW. Fundamentals of antimicrobial pharmacokinetics and pharmacodynamics. Springer, New York: 2014:137-46.
20. Tratselas A, Iosifidis E, Ioannidou M, Saoulidis S, Kollios K, Antachopoulos C, et al. Outcome of urinary tract infections caused by extended spectrum  $\beta$ -lactamase-producing Enterobacteriaceae in children. *Pediatr Infect Dis J* 2011;30:707-10.
21. Lee B, Kang SY, Kang HM, Yang NR, Kang HG, Ha IS, et al. Outcome of Antimicrobial Therapy of Pediatric Urinary Tract Infections Caused by Extended-Spectrum  $\beta$ -Lactamase-Producing Enterobacteriaceae. *Infect Chemother* 2013;45:415-21.
22. Han SB, Lee SC, Lee SY, Jeong DC, Kang JH. Aminoglycoside therapy for childhood urinary tract infection due to extended-spectrum  $\beta$ -lactamase-producing *Escherichia coli* or *Klebsiella pneumoniae*. *BMC Infect Dis* 2015;15:414.
23. Hyun HS, Kim JH, Cho MH, Park E, Ha IS, Cheong HI, et al. Low relapse rate of urinary tract infections from extended-spectrum beta-lactamase-producing bacteria in young children. *Pediatr Nephrol* 2019;34:2399-407.
24. CLSI. Performance Standards for Antimicrobial Susceptibility Testing; 24th ed. CLSI supplement M100. Wayne, PA: Clinical and Laboratory Standards Institute; 2014.
25. Rupp ME, Fey PD. Extended spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae: considerations for diagnosis, prevention and drug treatment. *Drugs* 2003;63:353-65.
26. Vardakas KZ, Tansarli GS, Rafailidis PI, Falagas ME. Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum  $\beta$ -lactamases: a systematic review and meta-analysis. *J Antimicrob Chemother* 2012;67:2793-803.
27. Nordmann P, Naas T, Poirel L. Global spread of Carbapenemase-producing Enterobacteriaceae. *Emerg Infect Dis* 2011;17:1791-8.
28. Pitout JD, Laupland KB. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. *Lancet Infect Dis* 2008;8:159-66.
29. Roberts KB. Urinary tract infection: clinical practice guideline for the diagnosis and management of the initial UTI in febrile infants and children 2 to 24 months. *Pediatrics* 2011;128:595-610.
30. Helm RE. Accepted but Unacceptable: Peripheral IV Catheter Failure: 2019 Follow-up. *J Infus Nurs* 2019;42:149-50.
31. Ullman AJ, Marsh N, Mihala G, Cooke M, Rickard CM. Complications of Central Venous Access Devices: A Systematic Review. *Pediatrics* 2015;136:e1331-44.
32. Tamma PD, Rodriguez-Bano J. The Use of Noncarbapenem  $\beta$ -Lactams for the Treatment of Extended-Spectrum  $\beta$ -Lactamase Infections. *Clin Infect Dis* 2017;64:972-80.
33. Pilimis B, Parize P, Zahar JR, Lortholary O. Alternatives to carbapenems for infections caused by ESBL-producing Enterobacteriaceae. *Eur J Clin Microbiol Infect Dis* 2014;33:1263-5.
34. Sharara SL, Amoah J, Pana ZD, Simner PJ, Cosgrove SE, Tamma PD. Is Piperacillin-Tazobactam Effective for the Treatment of Pyelonephritis Caused by Extended-Spectrum  $\beta$ -Lactamase-Producing Organisms? *Clin Infect Dis* 2020;71:e331-e7.
35. Son SK, Lee NR, Ko JH, Choi JK, Moon SY, Joo EJ, et al. Clinical effectiveness of carbapenems versus alternative antibiotics for treating ESBL-producing Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. *J Antimicrob Chemother* 2018;73:2631-42.